Showing results (41-50 of 238) with videos related to

Sort By:
Pageof 24
Nature Reviews. Clinical Oncology|April 5, 2012
Molecular prescreening to select patient population in early clinical trialsJordi Rodón, Cristina Saura, Rodrigo Dienstmann, et al.
Molecular and Cellular Biology|June 20, 2006
Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresisJoan J Bech-Serra, Belén Santiago-Josefat, Cary Esselens, et al.
Cancer Research|August 19, 2007
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implicationsGemma Armengol, Federico Rojo, Josep Castellví, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 16, 2016
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic GuidanceEric Wehrenberg-Klee, N Selcan Turker, Pedram Heidari, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2008
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation studyChris Twelves, José M Trigo, Rob Jones, et al.
The EMBO Journal|June 24, 2006
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translationJudit Anido, Maurizio Scaltriti, Joan Josep Bech Serra, et al.
Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.
JAMA Otolaryngology-- Head & Neck Surgery|July 9, 2016
Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical TrialJames Bonner, Jordi Giralt, Paul Harari, et al.
Bone|January 17, 2012
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I studyRosemary A Hannon, Richard D Finkelman, Glen Clack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly scheduleJosé Baselga, Xavier Carbonell, Noel-Jaime Castañeda-Soto, et al.
Pageof 24